Answers are grounded in this paper and cite their sources.
Critical narrative review synthesizes antimicrobial effectiveness of T. procumbens in humans, indicating its potential utility against resistant pathogens.
The escalating global crisis of antimicrobial resistance (AMR) has renewed scientific interest in bioactive plant-derived compounds as foundations for novel pharmaceuticals. Tridax procumbens L. (Asteraceae), a pantropical herb employed extensively in traditional medicine across Africa, Asia, and Latin America, has attracted considerable pharmacological interest over the past decade. This critical narrative review synthesizes primary research published between 2015 and 2025 on the antimicrobial effectiveness of T. procumbens against clinically significant human pathogens, with emphasis on phytochemical determinants, mechanistic pathways, methodological quality, and translational gaps. Drawing on 63 primary research articles and reviews identified through a structured search of PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Google Scholar, ethanolic and ethyl acetate leaf fractions are shown to exhibit potent activity against gram-positive pathogens, particularly Staphylococcus aureus (including MRSA), with minimum inhibitory concentration (MIC) values as low as 31.25 μg/mL. Moderate activity is documented against gram-negative species (Escherichia coli, Klebsiella pneumoniae, Salmonella typhi) and notable antifungal activity against Candida albicans. Principal bioactive constituents include luteolin, quercetin, lupeol, and β-sitosterol. Mechanistic evidence supports membrane disruption, DNA gyrase inhibition, biofilm suppression, and efflux pump inhibition. Inter-study variability is substantial, the evidence base is predominantly in vitro, and no human clinical trials have been conducted. T. procumbens possesses genuine but as yet unproven therapeutic potential; realizing this requires standardized extraction protocols, validated biomarker quantification, bioassay-guided isolation of pure active compounds, chronic toxicity profiling, and phased clinical evaluation.
No takes yet. Share an insight, caveat, or question.
rameshbhai et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: